4.0 Review

Peripartum Haemorrhage: Haemostatic Aspects of the New German PPH Guideline

Journal

TRANSFUSION MEDICINE AND HEMOTHERAPY
Volume 45, Issue 2, Pages 127-135

Publisher

KARGER
DOI: 10.1159/000478106

Keywords

Peripartum haemorrhage; Standard operating procedures; Uterotonics; Haemostasis; Tranexamic acid; Coagulation factor concentrates; Blood conservation

Funding

  1. Bayer Vital
  2. DRK blood donation service west
  3. CSL Behring
  4. Ferring
  5. Mitsubishi Pharma
  6. NovoNordisk
  7. Tem International
  8. Novo Nordisk
  9. Octapharma
  10. Haemonetics
  11. HICC GbR
  12. HICC
  13. AxonLab
  14. Roche Diagnostics
  15. Boehringer Ingelheim
  16. Pfizer
  17. Bristol Myers Squibb
  18. AstraZeneca
  19. Daichii Sankyo
  20. Vifor
  21. Cook Medical
  22. Clinical Innovations

Ask authors/readers for more resources

remains one of the main causes of maternal mortality world-wide. The German, Austrian and Swiss Societies of Gynaecology and Obstetrics have updated the current guidelines for the treatment of peripartum haemorrhage together with the German Society of Anaesthesiology and Intensive Care Medicine and the Society of Thrombosis and Haemostasis Research. The recommendations have been the result of a thorough review of the available scientific literature and a consensus process involving all members of the guideline group. A key element of the anaesthesiological and haemostatic management is the development of a multidisciplinary standard operating procedure combining surgical as well as medical and haemostatic treatments depending on the severity of bleeding. The guideline underscores the value of clinical and laboratory diagnostics of peripartum haemorrhage as early as possible, even pre-emptively. This allows for an early identification of causes of bleeding and a specific treatment. The guideline comprises evidence-based recommendations for the use of uterotonics, tranexamic acid and blood products such as factor concentrates, fresh frozen plasma, platelet concentrates, packed red blood cells, recombinant activated factor VII and desmopressin. In addition, recommendations for blood conservation strategies involving the use of cell salvage, permissive hypotension and transfusion triggers are given. (c) 2017 S. Karger GmbH, Freiburg

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available